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Christophe Heymes, Jane-Lise Samuel, Claire Lugnier, Marco Conti,
Rodolphe Fischmeister, Gre´goire Vandecasteele
Rationale: Multiple cyclic nucleotide phosphodiesterases (PDEs) degrade cAMP in cardiomyocytes but the role of
PDEs in controlling cAMP signaling during pathological cardiac hypertrophy is poorly defined.
Objective: Evaluate the -adrenergic regulation of cardiac contractility and characterize the changes in cardio-
myocyte cAMP signals and cAMP-PDE expression and activity following cardiac hypertrophy.
Methods and Results: Cardiac hypertrophy was induced in rats by thoracic aortic banding over a time period of
5 weeks and was confirmed by anatomic measurements and echocardiography. Ex vivo myocardial function was
evaluated in Langendorff-perfused hearts. Engineered cyclic nucleotide-gated (CNG) channels were expressed in
single cardiomyocytes to monitor subsarcolemmal cAMP using whole-cell patch-clamp recordings of the
associated CNG current (ICNG). PDE variant activity and protein level were determined in purified cardiomyo-
cytes. Aortic stenosis rats exhibited a 67% increase in heart weight compared to sham-operated animals. The
inotropic response to maximal -adrenergic stimulation was reduced by 54% in isolated hypertrophied hearts,
along with a 32% decrease in subsarcolemmal cAMP levels in hypertrophied myocytes. Total cAMP hydrolytic
activity as well as PDE3 and PDE4 activities were reduced in hypertrophied myocytes, because of a reduction of
PDE3A, PDE4A, and PDE4B, whereas PDE4D was unchanged. Regulation of -adrenergic cAMP signals by
PDEs was blunted in hypertrophied myocytes, as demonstrated by the diminished effects of IBMX (100 mol/L)
and of both the PDE3 inhibitor cilostamide (1 mol/L) and the PDE4 inhibitor Ro 201724 (10 mol/L).
Conclusions: -Adrenergic desensitization is accompanied by a reduction in cAMP-PDE and an altered modulation
of -adrenergic cAMP signals in cardiac hypertrophy. (Circ Res. 2009;105:784-792.)
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Stimulation of cardiomyocyte -adrenergic receptors (-ARs) by noradrenaline released from the sympathetic
nervous system is the most powerful mechanism to increase
cardiac output in response to stress or exercise. -ARs signal
primarily through Gs proteins, resulting in the activation of
adenylyl cyclases and the elevation in the intracellular con-
centration of the second messenger cAMP. The positive
chronotropic, inotropic, and lusitropic effects of cAMP on
cardiomyocytes are primarily mediated by the cAMP-
dependent protein kinase (PKA), which phosphorylates and
regulates many of the key proteins involved in cardiac
excitation-contraction coupling.1
-AR signaling is rapidly terminated through several
mechanisms that limit cAMP production, such as reuptake
and/or metabolism of noradrenaline, uncoupling and desen-
sitization of -ARs, and inactivation of Gs signaling on GTP
hydrolysis. Intracellular cAMP is degraded by cyclic nucle-
otide phosphodiesterases (PDEs), thus inactivating PKA.
Finally, protein phosphatases reverse the PKA-mediated ef-
fects on myocyte contraction by dephosphorylating the PKA
downstream targets. PDEs comprise a large group of isoen-
zymes that are divided into 11 PDE families based on their
substrate and inhibitor specificity and sequence homology.2,3
Of these, PDE3 and PDE4 contribute the majority of the
cAMP-hydrolytic activity in cardiomyocytes.4,5 PDE3 is en-
coded by 2 genes (PDE3A and PDE3B), with PDE3A being
the predominant form expressed in cardiomyocytes.6 The
PDE4 family consists of four genes (PDE4A to D), but only
PDE4A, PDE4B, and PDE4D appear to be expressed in rat
heart.7 These multiple PDEs contribute to the generation of
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intracellular cAMP microdomains within cardiomyocytes
that are thought to be critical for the specificity of cAMP
signaling.3,5
Whereas acute stimulation of cardiac output by the sym-
pathetic nervous system is essential for the adaptation of the
organism to its environment, chronic activation of the sym-
pathetic nervous system promotes a pathological remodelling
of the heart which may ultimately lead to heart failure (HF).8,9
It is well established that chronically elevated catecholamine
levels, which are a hallmark of HF, lead to the desensitization
of cardiac -AR signaling through several mechanisms that
limit cAMP production. These include the downregulation of
1-ARs; the uncoupling of 2-ARs from Gs; an increased
activity of -AR kinases; and an increase in Gi subunits,
which promotes the signaling of -ARs through Gi to inhibit
adenylyl cyclase. In canine models of HF, Gs and adenylyl
cyclases type V and VI are also decreased.10
In comparison, the signaling mechanisms acting down-
stream of cAMP synthesis have received much less attention.
In particular, only a few studies have investigated the poten-
tially critical role of PDEs in controlling cAMP signaling
during pathological cardiac hypertrophy (CH). These studies
focused on PDE3, reporting a decreased PDE3 expression
and/or activity in the failing heart.11 Such a decrease in PDE3
is thought to have adverse consequences on the heart because
it promotes cardiomyocyte apoptosis12 and exaggerates car-
diac dysfunction induced by chronic pressure overload.13
Although largely ignored until recently, a role of PDE4 in HF
is supported by the late onset cardiomyopathy developed in
mice with deletion of the PDE4D gene.14
Intrigued by these findings, we determined the expression
pattern of PDE3 and PDE4 enzymes and investigated the role
of these PDEs in the control of -AR cAMP signals in a rat
model of compensated CH. Using cyclic nucleotide-gated
(CNG) channels, we provide the first live cell recordings of
cAMP in hypertrophied cardiomyocytes and demonstrate that
PDE3 and PDE4 regulation of -AR cAMP signals is blunted
in hypertrophy. We report a decreased protein expression of
PDE3A, PDE4A, and PDE4B but not of PDE4D in hyper-
trophied cardiomyocytes compared to sham controls that is
paralleled by similar changes in cAMP-PDE activities for
these PDE subtypes. These results document profound de-
fects in the 2 main PDEs degrading cAMP in hypertrophied
myocytes.
Methods
All experiments performed conformed to the European Community
guiding principles in the care and use of animals (86/609/CEE, CE
Off J no. L358, 18 December 1986), the local ethics committee
(CREEA Ile-de-France Sud) guidelines, and the French decree no.
87-848 (J Off Re´publique Franc¸aise, 20 October 1987: pp 12245–
12248). Authorizations to perform animal experiments according to
this decree were obtained from the French Ministe`re de
l’Agriculture, de la Peˆche et de l’Alimentation (no. 92-283, June 27,
2007). Detailed methods are included in the Online Data Supplement
at http://circres.ahajournlas.org.
Briefly, CH was induced in rats by thoracic aortic banding over a
time period of 5 weeks and was confirmed by anatomic measure-
ments and echocardiography. Ex vivo myocardial function was
evaluated in Langendorff perfused hearts. Engineered CNG channels
were expressed in single isolated cardiomyocytes to monitor subsar-
colemmal cAMP using whole-cell patch-clamp recordings of the
associated CNG current (ICNG). PDE variant activity and protein
level were determined in purified cardiomyocytes.
Results
Induction and Characterization of Cardiac
Hypertrophy in Rats
To generate a model of CH, male Wistar rats were subjected
to aortic constriction over a time period of 5 weeks as
described in Methods. The development of CH was then
assessed through anatomic data and echocardiography (see
Table 1). Heart weight of the CH rats was significantly higher
(67%) than that of the sham-operated rats, whereas body
weight and tibia length were similar in both groups. The
weight of lung, liver, kidney, and right ventricle were also
unchanged (data not shown). Telediastolic interventricular
septum, telediastolic posterior wall thickness, and left ven-
tricular (LV) end diastolic diameter, as determined by echo-
cardiography were significantly larger in CH rats compared
to sham (Table 1). However, the fractional shortening was
similar between both groups, indicating a preserved LV
function in CH rats. From these data, we can classify this
model as compensated CH.15 Measurement of cell capaci-
tance, perimeter, and surface confirmed that LV myocytes
from CH rats exhibited substantial hypertrophy when com-
pared to sham-operated animals (Table 1).
Isolated Heart Function in Sham-Operated and
CH Rats
To further characterize our model, myocardial function
was evaluated using an isolated Langendorff heart prepa-
ration. As shown in Table 2, spontaneous heart rate was
similar between sham-operated and CH hearts and was
increased to the same extent by a saturating concentration
of the -AR agonist isoprenaline (ISO, 1 mol/L). Basal
LV developed pressure and maximal rate of contraction,
measured as the maximal value of LV dP/dtmax (maximal
Non-standard Abbreviations and Acronyms
-AR -adrenergic receptor
CH cardiac hypertrophy
CNG cyclic nucleotide gated
CRC concentration–response curve
Emax maximal effect
HF heart failure
IBMX isobutylmethylxanthine
ICNG CNG current
ISO isoprenaline
LV left ventricular
LV dP/dtmax maximal positive first derivative of left ventricular
pressure
LV dP/dtmax maximal negative first derivative of left ventricular
pressure
PDE phosphodiesterase
PKA cAMP-dependent protein kinase
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positive first derivative of LV pressure), were not different
between the 2 groups, nor was the maximal rate of cardiac
relaxation, measured as the maximal value of LV dP/dtmax
(maximal negative first derivative of LV pressure) (Table 2).
ISO (1 mol/L) increased these 3 parameters by 2- to 4-fold in
normal hearts. In contrast, the response to maximal -AR
stimulation was reduced in hypertrophied hearts (Table 2). To
further document this difference, concentration–response curves
(CRC) to ISO were generated for both groups. Figure 1A shows
the CRC obtained for LV dP/dtmax by fitting the experimental
data with the Hill function. The 2 resulting curves were statis-
tically different (Fischer test, P0.001), with a decreased max-
imal effect (Emax) of ISO in CH hearts (Emax was
8205.0182.7 mm Hg  sec1 in sham and 3758.724.4
mm Hg  sec1 in CH) but identical apparent potency (EC50
was 3.40.3 nmol/L in sham versus 3.30.2 nmol/L in CH).
Similar results were obtained when the hearts were electri-
cally paced (at 400 bpm). Thus, in this model of compensated
CH, basal cardiac function is preserved but the inotropic
reserve in response to -AR stimulation is reduced.
Subsarcolemmal -Adrenergic cAMP Signals in
Sham-Operated and CH Rat Cardiomyocytes
It is well established that -adrenergic control of cardiac
contractility is associated with changes in the particulate, but
not the soluble pool of cellular cAMP.16,17 To determine
whether the attenuated inotropic response to ISO in CH was
related to a decrease in plasma membrane cAMP, engineered
CNG channels were overexpressed in sham and CH cardio-
myocytes and the associated ICNG was recorded as an index of
subsarcolemmal cAMP.18 Figure 1B summarizes the results
of initial experiments in which the effect of ISO at 100
nmol/L was tested on sham and CH cardiomyocytes express-
ing either the low-affinity E583M CNGA2 channel (K1/2
cAMP10.3 mol/L) or the high-affinity C460W/E583M
CNGA2 channel (K1/2 cAMP1.4 mol/L). To correct for cell
size, ICNG density was calculated by dividing the current
amplitude by the cell capacitance for each experiment. As
shown in Figure 1B, E583M CNGA2 detected ISO-induced
cAMP signals in cardiomyocytes from sham-operated rats
(ICNG density was increased to 4.21.5 pA/pF in the presence
of 100 nmol/L ISO, n19) but not in cardiomyocytes from
CH rats (ICNG density was 0.70.2 pA/pF, n12). In
contrast, using the high-affinity C460W/E583M CNGA2
allowed unambiguous detection of -AR-dependent cAMP
signals in both groups. On average, ISO increased ICNG
density to 15.11.9 pA/pF (n28) in sham cardiomyocytes
and to 8.31.8 pA/pF (n24) in CH myocytes. These results
demonstrate a decrease in the subsarcolemmal concentration
of cAMP on -AR stimulation in hypertrophy. To fully
characterize the -AR response, CRCs to ISO were generated
in both groups using C460W/E583M CNGA2 (Figure 1C).
Consistent with the measurements of contractility of whole
hearts, ISO dose-dependently increased cAMP in sham and
CH cardiomyocytes, but maximal stimulation was attenuated
in the CH myocytes. Fit of the data to the Hill equation
yielded 2 statistically different curves (Fischer test, P0.001)
Table 1. Cardiac Phenotype of Sham-Operated and
Hypertrophic Rats
Sham CH
P
Parameter
Value n
Parameter
Value n
Anatomy
BW (g) 3186 32 3167 33 NS
TL (cm) 3.60.03 32 3.60.04 33 NS
HW (g) 1.290.04 32 2.150.12 33 0.001
HW/BW (mg/g) 4.10.1 32 6.80.3 33 0.001
HW/TL (mg/cm) 36313 32 60537 33 0.001
Echocardiography
TD IVS (cm) 0.0830.002 6 0.1400.005 6 0.001
TD PW (cm) 0.0900.004 6 0.1550.007 6 0.001
LVEDD (cm) 0.6630.016 6 0.540.02 6 0.001
FS (%) 56.22.2 6 55.82.4 6 NS
Cell parameters
Cell capacitance (pF) 1735 84 2148 64 0.001
Perimeter (m) 2554 63 2954 60 0.01
Surface (m2) 236862 63 314084 60 0.001
All data are expressed as meansSEM. BW indicates body weight; FS,
fractional shortening; HW, heart weight; LVEDD, left ventricular end diastolic
diameter; n, no. of animals in each group for anatomic and echocardiographic
data or no. of cells in each group for cell parameters; TD IVS, telediastolic
interventricular septum; TD PW, telediastolic posterior wall; TL, tibia length.
Statistically significant differences between CH and sham-operated rats are
indicated with a P value.
Table 2. Basal and ISO-Stimulated Function of Hearts Isolated
From Sham-Operated and CH Rats
Sham CH
P
Parameter
Value n
Parameter
Value n
HR (bpm)
Baseline 2487 5 23117 7 NS
ISO
(1 mol/L)
35612* 5 34417* 7 NS
LVDP (mm Hg)
Baseline 73.54.2 5 77.17.2 7 NS
ISO
(1 mol/L)
152.09.0* 5 87.69.3 7 0.001
LV dP/dtmax
(mm Hg  sec1)
Baseline 1958.6164.9 5 1846.2177.3 7 NS
ISO
(1 mol/L)
8428.3613.5* 5 3757.2464.8† 7 0.001
LV dP/dtmax
(mm Hg  sec1)
Baseline 1283.272.1 5 1393.6140.5 7 NS
ISO
(1 mol/L)
5662.6395.8* 5 2564.6253.8† 7 0.001
The hearts were perfused with oxygenated Krebs–Henseleit solution con-
taining 1.25 mmol/L Ca2	o as described in Methods. HR indicates heart rate;
LVDP, left ventricular developed pressure. Values are meansSEM. Statisti-
cally significant differences within one group are indicated as *P0.001;
†P0.01. Statistically significant differences between CH and sham-operated
rats are indicated with a P value.
786 Circulation Research October 9, 2009
 by guest on O
ctober 19, 2017
http://circres.ahajournals.org/
D
ow
nloaded from
 
with a decreased maximal effect in hypertrophy (Emax was
15.10.7 pA/pF in sham versus 10.30.2 pA/pF in CH
cardiomyocytes) but similar apparent potency (EC50 was
9.92.3 nmol/L in sham versus 6.20.7 nmol/L in CH
cardiomyocytes). CNGA2 channel expression was the same
in sham and CH myocytes as indicated by immunoblot
analysis (Online Figure I). In contrast, the response to the
forskolin analogue L-858051 (100 mol/L) was identical in
sham and CH cardiomyocytes (30.33.0 pA/pF in sham
versus 29.45.7 pA/pF in CH cardiomyocytes; Figure 1D).
Because, at this concentration, L-858051 was shown to
saturate the probe,19 this result only indicates a similar density
of functional CNG channels in sham and CH cardiomyocytes.
Thus, the 32% decrease in maximal ISO response in CH
cells reflects a real decrease in the concentration of cAMP at
the membrane.
Modulation of -Adrenergic cAMP Signals by
PDEs in Sham and CH Cardiomyocytes
As a first experiment to elucidate the role of PDEs on cAMP
signals in sham-operated and CH rat hearts, the effect of the
general PDE inhibitor IBMX was tested in cardiomyocytes
using the low-affinity E583M CNGA2 channel. We showed
previously that 100 mol/L IBMX had no effect on basal
ICNG in cardiomyocytes expressing the E583M CNGA2
channel.18 As shown in Figure 2, the effects of IBMX in
combination with 100 nmol/L ISO are compared. Although
IBMX increased the response of ICNG to ISO in both sham
(Figure 2A) and CH myocytes (Figure 2B), the response
remained on average 50% smaller in CH cells (Figure 2C).
Because most of the cAMP hydrolytic activity is inhibited at
the concentration of IBMX used,20 this 50% difference
between sham and CH cardiomyocytes likely reflects a
commensurate reduction in cAMP synthesis. Using the
higher-affinity C460W/E583M CNGA2 channel to elicit
larger basal responses to ISO, we evaluated the contributions
of PDE3 and PDE4 to the -AR response. Preliminary
experiments were performed to check the effect of global
PDE inhibition on basal ICNG in rat ventricular myocytes
expressing the C460W/E583M CNGA2 channel. In agree-
ment with our previous reports,5,21 global PDE inhibition with
IBMX (100 mol/L) failed to significantly increase the
current in sham (ICNG was 0.90.5 pA/pF in the presence of
IBMX and 17.34.4 pA/pF in the presence of 100 nmol/L
ISO; n3) and CH cardiomyocytes (ICNG was 1.10.45
pA/pF in the presence of IBMX and 5.40.8 pA/pF the
presence of 100 nmol/L ISO; n6). As shown in Figure 3, the
results were quite different on -AR stimulation. In sham
cardiomyocytes, the effect of ISO on ICNG was potentiated
2-fold on PDE3 inhibition with cilostamide (1 mol/L)
and 3- to 5-fold on PDE4 inhibition with Ro 201724
(10 mol/L) (Figure 3A, 3C, and 3D). In CH cardiomyo-
cytes, cilostamide potentiated the ISO response by only
40%, whereas Ro 201724 increased the ISO response
2-fold (Figure 3B, 3C, and 3D). Consequently, the
responses of ICNG to ISO in combination with either PDE
inhibitor were significantly reduced in CH versus sham
cells (P0.01; Figure 3C and 3D).
Figure 1. -AR responses in whole hearts
and isolated ventricular myocytes from
sham and CH rats. A, CRC to ISO on LV
dP/dtmax used as an index of cardiac
contractility in 5 normal hearts and 7
hypertrophied hearts. B, Comparison of
the effect of ISO (100 nmol/L) on ICNG
density in sham (black bars) and hyper-
trophied (CH) (white bars) cardiomyocytes
using the low- and high-affinity CNG
channels mutants: E583M CNGA2 and
C460W/E583M CNGA2, respectively. ICNG
was measured every 8 seconds at 50
mV from a holding potential of 0 mV. The
number of cells tested from 2 normal
hearts and 3 hypertrophied hearts for
E583M CNGA2 and from 18 normal
hearts and 19 hypertrophied hearts for
E583M/C460W CNGA2 is indicated in
brackets above the bars. Statistically sig-
nificant differences in ICNG density
between sham-operated and CH cardio-
myocytes are indicated as *P0.05. C,
CRC to ISO on ICNG density in cardio-
myocytes from 16 hypertrophied hearts
(CH) (dash line) and 13 normal hearts
(Sham) (continuous line) using C460W/
E583M CNGA2. Cells were first super-
fused with control external Ringer solution
and then exposed to increasing concen-
trations of ISO. Data represent the
meansSEM of the number of cardio-
myocytes indicated near each data point.
D, Effect of the forskolin analog L-858051
(100 mol/L) on ICNG density in sham (black bars) and hypertrophied (CH) (white bars) cardiomyocytes using C460W/E583M CNGA2.
Data represent the meansSEM of the number of cells (from 23 normal hearts and 21 hypertrophied hearts) indicated near the bars.
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Expression of PDE3 and PDE4 Isoforms in Sham
and CH Cardiomyocytes
The above results suggest that in addition to a decreased
-AR cAMP production, cAMP degradation by PDE3 and
PDE4 is also decreased in CH cardiomyocytes. To test this
hypothesis further, the expression of PDE3 and PDE4 pro-
teins was measured in cardiomyocytes isolated from sham-
operated (n6) or CH rats (n4). Equal amounts of proteins
prepared from cardiomyocytes isolated from CH or sham-
operated animals were separated on SDS-PAGE and PDE3A,
PDE4A, PDE4B, and PDE4D proteins were subsequently
detected by Western blotting using PDE subtype-selective
antibodies. Detergent extracts prepared from brain and heart
of PDE knockout mice and wild-type control mice were
analyzed on the same blots to control for the specificity of the
antibodies. As shown in Figure 4A, all immunoreactive bands
detected with PDE4 subtype–selective antibodies in tissues of
wild-type mice were not present in the respective PDE4
knockout tissue. This finding confirms the specificity of the
antibodies used and indicates that the proteins detected in the
rat heart, given their identical migration on SDS-PAGE, are
authentic PDEs. Most PDEs are expressed as multiple vari-
Figure 2. Regulation of -AR cAMP sig-
nals by PDEs in sham and hypertrophied
cardiomyocytes. Subsarcolemmal cAMP
signals were recorded by measuring ICNG
in sham (A) and CH (B) cardiomyocytes
expressing E583M CNGA2. Cells were
superfused with control external Ringer
solution and then challenged with ISO
(100 nmol/L) in the absence or presence
of IBMX (100 mol/L) for the periods indi-
cated with horizontal lines. The individual
ICNG traces shown on top were recorded
at the times indicated by the correspond-
ing letters on the graph below. C, Sum-
mary of the responses shown in A and B.
Data are expressed as meansSEM. The
numbers above the bars represent cardio-
myocytes isolated from 2 normal hearts
and 3 hypertrophied hearts. Asterisks and
dollars signs indicate statistically signifi-
cant differences (paired t test) resulting
from the treatment with IBMX or statisti-
cally significant differences (unpaired t
test) between hypertrophied (CH) and
sham cardiomyocytes, respectively, and
are indicated as: $P0.05; **P0.01;
***P0.001.
Figure 3. Regulation of -AR cAMP signals
by PDE3 and PDE4 in sham and hypertro-
phied cardiomyocytes. Subsarcolemmal
cAMP signals were recorded by measuring
ICNG in sham (A) and CH (B) cardiomyocytes
expressing C460W/E583M CNGA2. Cells
were superfused with control external Ringer
solution and then challenged with different
drugs for the periods indicated with horizontal
lines. The individual ICNG traces shown on top
were recorded at the times indicated by the
corresponding letters on the graph below. C
and D, Summary of the responses shown in
A and B, represented either in absolute cur-
rent density (C) or in percentage increase
over the ISO response (D). All data are
expressed as meansSEM. The numbers
above the bars represent cardiomyocytes
isolated from 2 normal and 5 hypertrophied
hearts. Asterisks and dollars signs indicate
statistically significant differences (paired t
test) resulting from the treatment with PDE
inhibitors or statistically significant differences
(unpaired t test) between CH and sham car-
diomyocytes, respectively, and are indicated
as: $P0.05; **P0.01; $$P0.01;
***P0.001.
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ants through the use of different promoters and alternative
splicing, which explains the presence of multiple immunore-
active bands detected in Western blotting for several PDE
subtypes. Three immunoreactive bands migrating at approx-
imately 125, 106, and 97 kDa were detected for PDE3A in rat
cardiomyocytes. All 3 appeared to be decreased in CH
myocytes compared to sham cells. Probing cardiomyocyte
extracts with PDE4A-selective antibodies also labeled 3
bands of approximately 105, 95, and 79 kDa. All PDE4A
immunoreactive signals were attenuated in CH myocytes
compared to sham. A single band migrating at 92 kDa was
detected in ventricular cardiomyocytes for PDE4B. Its ex-
pression was decreased in CH cardiomyocytes. A single band
migrating at 91 kDa was detected in cardiomyocytes
extracts using PDE4D-selective antibodies. Migration of this
band corresponds to the migration of PDE4D variants
PDE4D3, PDE4D8, and PDE4D9.22 In contrast to the other
PDE subtypes analyzed, the PDE4D immunoreactive signal
intensity was not significantly different in CH compared to
sham cells (Figure 4B).
cAMP-PDE Activities in Sham and
Hypertrophied Cardiomyocytes
To determine whether changes in PDE protein expression are
reflected in similar changes of PDE activity, total cAMP-
hydrolytic activity in isolated cardiomyocytes from CH and
sham-operated rats was measured (Figure 5). Total cAMP-
PDE, as well as PDE3 and PDE4 activities, was significantly
decreased by 42%, 42%, and 53%, respectively (Figure 5A).
To further dissect the contributions of single PDE4 subtypes,
total extracts from cardiomyocytes isolated from sham (n5)
and CH (n4) rats were immunoprecipitated using subtype-
specific antibodies against PDE4A, PDE4B, and PDE4D, and
the PDE activity recovered in the immunoprecipitation pellets
was assayed (Figure 5B). The activity of both PDE4A and
PDE4B was significantly reduced in CH cells compared to
sham. Conversely, PDE4D activity was not significantly
different between the 2 groups.
Discussion
With this study, we provide evidence that cardiac hypertro-
phy induced by chronic pressure overload in the rat is
associated with major changes in the cAMP signaling ma-
chinery that controls excitation–contraction coupling. To-
gether with marked -AR desensitization, we demonstrate a
decrease in relative activities and protein densities for PDE
isoforms belonging to the PDE3 and PDE4 families, the
major cAMP hydrolyzing forms expressed in cardiomyocytes
from different species.
In rat cardiomyocytes, PDE3 and PDE4 contribute between
70% and 90% of the total cAMP-hydrolyzing activity.4,18,21,23
Therefore, a molecular characterization of the various
PDE3A and PDE4 isoforms expressed in cardiomyocytes was
undertaken. The 3 immunoreactive bands of PDE3A detected
here in the rat heart likely represent the counterparts of human
PDE3A1, PDE3A2, and PDE3A3 because of their similar
migration in SDS-PAGE.19 Of the 3 immunoreactive species
detected for PDE4A, the long 95-kDa form was previously
detected in rat heart but not identified.7 To our knowledge,
Figure 4. Expression of PDE3 and PDE4
proteins in sham and hypertrophied car-
diomyocytes. Equal amounts of proteins
from ventricular myocytes isolated from
CH (n4) and sham-operated (n6) rat
hearts were separated on SDS-PAGE and
revealed with PDE subtype-specific anti-
bodies. Whole brain (PDE4A, PDE4B, and
PDE4B) and total heart extracts (PDE3A)
of wild-type (WT) and the respective PDE
knockout (KO) mice were loaded as im-
munoblot controls (IB ctr.). Calsequestrin
(Calseq) was used as a loading control. A,
Shown are representative blots. B, Quan-
tification of all data obtained in several
immunoblots from 6 sham-operated sam-
ples and 4 CH samples.
Figure 5. Pattern of cAMP-PDE activities in sham and hypertro-
phied cardiomyocytes. A, PDE activity in sham and CH cardio-
myocytes using 1 mol/L cAMP as substrate. PDE3 and PDE4
activities are defined as the fraction of the total PDE activity
inhibited by cilostamide (1 mol/L) or rolipram (10 mol/L),
respectively. B, Detergent extracts from sham and CH cardio-
myocytes were immunoprecipitated with PDE4 subtype–specific
antibodies as described in Methods. The PDE activities recov-
ered in the immunoprecipitation pellets are reported. The num-
ber of samples analyzed for each group is shown in brackets
above the bars. All data show the meansSEM. Statistically sig-
nificant differences in PDE activity between CH and sham-
operated rats are indicated as: *P0.05; **P0.01; ***P0.001.
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the 2 others species migrating at 105 and 79 kDa were not
described in cardiomyocytes. The size of the first corresponds
to a long form, such as PDE4A5, PDE4A8, PDE4A10, or
PDE4A11.24,25 The short form detected likely corresponds to
PDE4A1, which has a mobility similar to the form migrating
at 75 kDa in rat brain.24 Only 1 immunoreactive band at
92 kDa was detected in cardiomyocytes for PDE4B. This
species was previously reported in rat ventricle24 and likely
represents long PDE4B form(s), such as PDE4B1 and/or
PDE4B3, for which transcripts were detected in rat heart.7 In
contrast to earlier studies, we could not detect expression of
PDE4B2, which is expected to migrate at 75 kDa.4,7
Finally, we detected 1 PDE4D immunoreactive band that
exhibited a migration similar to splice variants PDE4D3,
PDE4D8, and PDE4D9.22 These diverse PDE isoforms have
been shown to be localized in specific compartments, so as to
exert a local control of cAMP signaling; for instance,
PDE4D3 associates with the ryanodine receptor complex14
and with the IKs potassium channel complex26; PDE4D5
associates with -arrestin near the 2-AR27; and PDE4D8 has
been shown to bind to the 1-AR.28 In addition, a long
isoform of PDE4D was shown recently to coimmunoprecipi-
tate with SERCA2a.29
When comparing sham and hypertrophied cardiomyocytes,
profound quantitative differences were observed: relative
activity and protein expression of PDE3A, PDE4A, and
PDE4B were decreased in hypertrophy, whereas that of long
PDE4D isoforms remained unchanged. Although our exper-
iments do not exclude the possibility that changes in other
PDE families also occur in cardiac hypertrophy, the observed
decrease in PDE levels is comparable to the reduction of
1-ARs30 and the sarcoplasmic reticulum Ca2 ATPase31
previously reported in rat heart using a similar model of
hypertrophy. Although the mechanisms were not determined,
our findings suggest that the genes encoding PDE3A,
PDE4A, and PDE4B are not part of the hypertrophic pro-
gram. A small number of previous studies have investigated
the variations of PDE3 and PDE4 during CH with contradic-
tory results.32 In dogs with CH attributable to aortic valve
stenosis, cAMP-PDE activity was reported to be un-
changed,33,34 whereas PDE3 and PDE4 expression and activ-
ities were found to be enhanced in Dahl salt–sensitive rats.35
Our results are consistent with a decreased expression of
PDE3A in rodent models of CH induced by chronic infusion
of isoprenaline or angiotensin II12 and with several studies
showing a reduction in PDE3 expression and/or activity at the
HF stage.36–39 However, some studies found no difference in
PDE3 activity during HF.34,40 Concerning PDE4, a constant
mRNA level for PDE4D was reported in dog with HF,37
which is consistent with what we observe in rats with CH.
However, the PDE4D3 isoform associated to RyR2 was
found decreased in human HF.20 This difference might be
attributable to the different species or to the fact that we
measured the total cellular PDE4D pool. Therefore, a de-
crease in PDE4D3 could be compensated by an increase in
another splice variant such as PDE4D8 or PDE4D9, which
are also expressed in heart.26 It should be noted that in this
study, protein expression and activity measurements were
performed using highly purified cardiomyocytes, thus exclud-
ing possible variations attributable to other cell types present
in the heart.
Despite an important decrease in the 2 main PDEs involved
in cAMP hydrolysis, there was a marked impairment of
contractile responsiveness to isoprenaline in hypertrophied
hearts (Figure 1A) that correlated with reduced subsarcolem-
mal cAMP levels on -AR stimulation in hypertrophied cells
(Figure 1B and 1C). These results indicate that the PDE
diminution was unable to compensate for -AR desensitiza-
tion. They are in agreement with numerous studies showing a
loss of the -AR inotropic reserve,41–44 a decreased -AR
density,30,41,45 a decreased ISO-stimulated cAMP forma-
tion,46,47 and a decreased -AR stimulation of the L-type
Ca2 current48 in rodent models of CH induced by pressure
overload. In contrast, the response to the forskolin analog
L-858051 at 100 mol/L was unchanged (Figure 1D). We
showed previously that this concentration of L-858051 satu-
rates the CNG channels.19 Thus, this result indicates that the
same density of functional channels was expressed in normal
and hypertrophied cells.
In conclusion, our study provides strong biochemical
and functional evidence for a decreased cAMP-hydrolytic
reserve during cardiac hypertrophy and identifies PDE3A,
PDE4A, and PDE4B as being specifically altered. PDE
downregulation in CH might be regarded as an initial
adaptive process because it partly compensates for the
deficit in cAMP synthesis. However, such PDE remodeling
may be maladaptive in the long term, because of a loss of
cAMP compartmentation.3,18 This in turn may cause unre-
stricted diffusion of cAMP and chronic activation of
cAMP effectors, such as PKA and the exchange factor for
Rap1, Epac, both of which were shown to induce patho-
logical cardiac hypertrophy.49 –51
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ONLINE DATA SUPPLEMENT 
Abi-Gerges et al. SUPPLEMENT MATERIAL 2
Materials and Methods 
 
Reagents 
Isoprenaline (ISO) and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Sigma (St. 
Louis, MO, USA). Cilostamide was obtained from Tocris Bioscience (Ellisville, MI, USA). 
L-858051 (L-85; a hydrosoluble forskolin analogue) was from Calbiochem (San Diego, CA, 
USA). Ro 201724 (Ro) was kindly provided by Hoffman-La-Roche (Basel, Switzerland). The 
antibody against calsequestrin was obtained from Affinity BioReagents (Golden, CO, USA). 
PDE3A was detected in Western blotting using a rabbit polyclonal anti-PDE3A antibody 
kindly provided by Dr. Chen Yan (Columbia University, NY, USA). The PAN-selective 
antibodies against PDE4A (AC55), PDE4B (K118) and PDE4D (M3S1) that were used for 
immunoprecipitation (IP) experiments have been described previously.1 PDE4A and PDE4B 
were detected in Western blotting using rabbit polyclonal antibodies generated against the 
specific C-termini of these PDEs. Mouse monoclonal antibodies against PDE4D and CNGA2 
were kindly provided by ICOS Corporation (Bothell, WA, USA) and by Dr. Frank Mueller 
(Forschungszentrum Jülich, Jülich, Germany), respectively. 
 
Induction of Cardiac Hypertrophy in Rats 
77 male Wistar rats were used in this study. Left ventricular hypertrophy was induced at three 
weeks of age (body weight<60g). The animals were anesthetized (pentobarbital 60 mg/kg) 
and a stainless steel hemoclip of 0.6 mm ID was placed on the ascending aorta via thoracic 
incision.2 Age-matched control animals (sham-operated) underwent the same procedure 
without placement of the clip. 5 weeks after surgery, 6 rats from each group were 
anesthetized with isofluorane and subjected to echocardiography as described previously.3 All 
other rats were sacrificed 5 weeks after surgery and body, heart, lung, liver and kidney were 
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weighed. Tibia length was measured using a vernier caliper (Table 1). Rats that exhibited 
signs of congestive HF (i.e. ascites, serous cavity effusion, or necrotic lungs, kidney or liver) 
were excluded from the study. The hearts from all other animals were either digested to 
obtain individual myocytes or used for Langendorff heart studies, as described in the next 
sections. All procedures conform to the European Community guiding principles in the care 
and use of animals (86/609/CEE, CE Off J n°L358, 18 December 1986), the local ethics 
committee (CREEA Ile-de-France Sud) guidelines and the French decree n°87/748 of 
October 19, 1987 (J Off République Française, 20 October 1987, pp. 12245-12248). 
Authorizations to perform animal experiments according to this decree were obtained from 
the French Ministère de l'Agriculture et de la Forêt (nº7475, May 27, 1997). 
 
Ex vivo Physiology 
 
Rats were anesthetized by intraperitoneal injection of pentobarbital (150 mg/kg). The heart 
was quickly removed and placed in oxygenated Krebs-Henseleit solution (95% O2 and 5 % 
CO2 , pH 7.35) containing (in mmol/L): NaCl 113, NaHCO3 25, KCl 4.7, KH2PO4 1.2, 
MgSO4 1.2, CaCl2 1.25, glucose 11, Na pyruvate 5, and mannitol 1.1. The aorta was 
cannulated and perfused by the Langendorff method with oxygenated Krebs-Henseleit 
solution at constant pressure (75 mmHg, temperature 37±0.2°C). A latex water-filled balloon 
was inserted into the left ventricular chamber and connected to a pressure transducer 
(Statham gauge Ohmeda, Bilthoven, Holland) for continuous measurement of heart 
contractility. Heart rate, left ventricular developed pressure (LVDP) and the first derivatives 
of LV pressure (LV +dP/dtmax and LV -dP/dtmax) were measured online using a dedicated 
software (Emka technologies data analyzer, Paris, France). For each heart, the experiment 
started with a progressive increase of the latex balloon inserted inside the left ventricle to 
generate a ventricular volume-developed pressure relationship. When the maximal developed 
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pressure was reached, ten minutes of equilibration in isovolumic working conditions were 
imposed before infusing increasing concentrations of isoprenaline (from 1 nmol/L to 1 
µmol/L). 
 
Isolation of Adult Rat Ventricular Myocytes 
Hearts were mounted on a Langendorff apparatus and perfused through the coronaries with 
collagenase A (Roche, Meylan, France) as described previously.4 Digestion time was 50 min 
for hearts from sham-operated animals and varied between 90 and 120 min for hypertrophic 
hearts. At the end of the enzymatic digest, the left ventricles were excised, chopped finely, 
and agitated manually to dissociate individual myocytes. A portion of the freshly isolated 
cells was infected with adenoviruses encoding CNGA2 channels for measurement of 
intracellular cAMP signals as described below. The remaining cells were frozen in liquid 
nitrogen and subsequently used to determine PDE expression patterns by Western blotting or 
PDE activity assay.  
 
Preparation of Protein Extracts from Cardiomyocytes 
Left ventricular myocytes isolated from sham-operated and cardiac hypertrophy (CH) rats 
were homogenized in ice-cold buffer containing (in mmol/L): NaCl 150, Hepes 20 (pH 7.4), 
EDTA 2, and supplemented with 10% Glycerol, 0.5% NP40, 1 µmol/L microcystin-LR, and 
Complete Protease Inhibitor Tablets from Roche Diagnostics (Basel, Switzerland). Cell 
lysates were centrifuged at 14,000 g and 4°C for 20 min, and supernatants were either used 
directly for PDE assay or Western blotting or first subjected to IPs as described below.  
To determine the expression of CNG channels, adult rat ventricular myocytes were 
homogenized 24 h after infection with C460W/E583M CNGA2 adenoviruses in ice cold 
buffer containing (in mmol/L): NaCl 150, Tris HCl (pH 7.5) 20, EGTA 5, NaVO3 1, sodium 
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fluoride 20, glycerophosphate 20, and supplemented with 1% Triton-X 100, 0.1% Tween 20, 
and a protease inhibitor cocktail from Calbiochem (LaJolla, CA, USA). Cell lysates were 
centrifuged at 10,000 g and 4°C for 10 min and the resulting supernatants were used to 
measure channel expression by Western blotting. 
 
Immunoprecipitation of PDE4 Subtypes from Protein Extracts 
For IPs, the respective PDE4 subtype-specific antibodies were coupled to 25 µL of Protein G-
Sepharose beads, which were then incubated with protein extracts from adult rat ventricular 
myocytes (each 1 mg protein) for 2 h at 4°C. The beads were pelleted, washed three times 
with cell lysis buffer, and the resulting IP pellets were subjected to PDE activity assays as 
described below. 
 
PDE Assay 
Cyclic AMP-PDE activity was measured according to the method of Thompson and 
Appleman as described in detail previously.5 In brief, samples were assayed in a reaction 
mixture of 200 µL containing 40 mmol/L Tris-HCl (pH 8.0), 1 mmol/L MgCl2, 1.4 mmol/L 
β-mercaptoethanol, 1 µmol/L cAMP, 0.75 mg/mL bovine serum albumin, and 0.1 µCi of 
[3H]cAMP for 30 min at 33°C. The reaction was terminated by heat inactivation in a boiling 
water bath for 1 min. The PDE reaction product 5'-AMP was then hydrolyzed by incubation 
of the assay mixture with 50 µg of Crotalus atrox snake venom for 20 min at 33°C, and the 
resulting adenosine was separated by anion exchange chromatography using 1 mL of AG1-
X8 resin (BioRad, Hercules, CA, USA) and quantitated by scintillation counting. PDE3 and 
PDE4 activities were defined as the fraction of cAMP-PDE activity inhibited by 1 µmol/L 
cilostamide or 10 µmol/L rolipram, respectively. 
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Single Cell Measurement of cAMP Signals 
To measure real-time cAMP signals, cardiac myocytes were infected with adenoviruses 
encoding for two mutants of the cyclic-nucleotide gated CNGA2 channel, E583M CNGA2 
and C460W/E583M CNGA2. The CNGA2 channel carrying the E583M mutation exhibits a 
lower affinity for cAMP (K1/2 cAMP=10.3 µmol/L) compared to the channel carrying the 
C460W/E583M double mutation (K1/2 cAMP=1.4 µmol/L).6 Freshly isolated adult rat 
ventricular myocytes were cultured in Minimum Essential Medium (M 4780; Sigma, St. 
Louis, MO) containing 1.2 mM Ca2+, 2.5% fetal bovine 
serum (FBS, Invitrogen, Cergy-Pontoise, France), 1% penicillin-streptomycin and 2% 
HEPES (pH 7.6) and plated on laminin-coated culture dishes (10 µg/ml laminin, 2 h) at a 
density of 104 cells per dish. The cells were left to adhere for 1 h in a 95% O2, 5% CO2 
atmosphere at 37 °C, before the medium was replaced with 300 µl FBS-free MEM containing 
the respective adenovirus at a multiplicity of infection of 600 pfu/per cell. 24 h after virus 
infection, cell membrane capacitance and ICNG were measured using the patch-clamp 
technique in the whole-cell configuration as previously described.7 Cell membrane 
capacitance was determined as the current elicited by a voltage ramp at 1V/s between -90 mV 
and -70 mV. ICNG was measured at -50 mV in 200 ms steps from a holding potential of 0 mV. 
Extracellular solution contained (in mmol/L): NaCl 107.1, CsCl 20, NaHCO3 4, NaH2PO4 
0.8, D-Glucose 5, sodium pyruvate 5, HEPES 10, nifedipine 0.001, and was adjusted to pH 
7.4 with NaOH. Patch electrodes (0.5-1 MΩ) were filled with intracellular solution 
containing (in mmol/L): CsCl 118, EGTA 5, MgCl2 4, sodium phosphocreatine 5, Na2ATP 
3.1, Na2GTP 0.42, CaCl2 0.062 (pCa 8.5), HEPES 10, and was adjusted to pH 7.3 with 
CsOH. All experiments were done at room temperature (19-25°C), and the temperature did 
not vary by more than 1°C in a given experiment. 
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Data Analysis 
Cellular hypertrophy was evaluated by measuring cell surface and cell perimeter using Image 
J (Wayne Rasband, National Institutes of Health, USA) as well as cell membrane 
capacitance. ICNG amplitude was measured at the end of the 200 ms pulse at -50 mV. ICNG 
density (dICNG) was calculated for each experiment as the ratio of current amplitude to cell 
capacitance (Cm). In each experimental condition, the response of dICNG to a drug was 
expressed relative to the ‘basal current’ obtained in control extracellular solution following 
the relation: ‘response’=(ICNG-‘basal current’)/Cm. All data are expressed as mean ± S.E.M. 
Paired Student’s t-test was used for statistical evaluation within the same group. When two 
groups were compared, unpaired Student t-test was used. Concentration-response curves 
(CRC) of ISO on ICNG and LV +dP/dtmax, were generated by fitting the data to the Hill 
equation, dICNG=Emax/(1+(EC50/[ISO])n) or LV +dP/dtmax=Emax/(1+(EC50/[ISO])n), where Emax 
is the maximal effect, EC50 is the ISO concentration required to produce half of Emax, and n is 
the Hill coefficient. The CRC obtained in both groups were compared using a Fisher test; and 
a difference was considered statistically significant when p was <0.05. 
 
References 
 
 1.  Richter W, Jin SL, Conti M. Splice variants of the cyclic nucleotide phosphodiesterase 
PDE4D are differentially expressed and regulated in rat tissue. Biochem J. 
2005;388:803-811. 
 2.  Samuel J-L, Bertier B, Bugaisky L, Marotte F, Swynghedauw B, Schwartz K, 
Rappaport L. Different distributions of microtubule filaments and isomyosins during the 
onset of cardiac hypertrophy in he rat. Eur J Cell Biol. 1984;34:300-306. 
 3.  Loyer X, Oliviero P, Damy T, Robidel E, Marotte F, Heymes C, Samuel JL. Effects of 
 
Abi-Gerges et al. SUPPLEMENT MATERIAL 8
sex differences on constitutive nitric oxide synthase expression and activity in response 
to pressure overload in rats. Am J Physiol Heart Circ Physiol. 2007;293:H2650-8. 
 4.  Verde I, Vandecasteele G, Lezoualc'h F, Fischmeister R. Characterization of the cyclic 
nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ 
current in rat ventricular myocytes. Br J Pharmacol. 1999;127:65-74. 
 5.  Richter W, Conti M. Dimerization of the type 4 cAMP-specific phosphodiesterases is 
mediated by the upstream conserved regions (UCRs). J Biol Chem.  2002;277:40212-
40221. 
 6.  Rich TC, Tse TE, Rohan JG, Schaack J, Karpen JW. In vivo assessment of local 
phosphodiesterase activity using tailored cyclic nucleotide-gated channels as cAMP 
sensors. J Gen Physiol. 2001;118:63-77. 
 7.  Rochais F, Abi-Gerges A, Horner K, Lefebvre F, Cooper DMF, Conti M, Fischmeister 
R, Vandecasteele G. A specific pattern of phosphodiesterases controls the cAMP 
signals generated by different Gs-coupled receptors in adult rat ventricular myocytes. 
Circ Res. 2006;98:1081-1088. 
 
Abi-Gerges et al. SUPPLEMENT MATERIAL 
 
9
 
 
%
 re
la
tiv
e 
to
 S
ha
m
(n
or
m
al
iz
ed
to
 
Ca
ls
eq
ex
pr
es
si
on
)
CNGA2 
(73 kDa)
Calseq
(55 kDa)
Sh
am
CHSh
am
Sh
am
CHCH Sh
am
NI Ad-C460W/E583M
(3) (3)
0
20
40
60
80
100
120
Ad-C460W/E583M
A
B
Sham
CH
 
 
 
 
 
 
 
 
 
 
 
 
 
Online Figure 1. Expression of C460W/E583M CNGA2 in sham and CH adult rat 
ventricular myocytes. (A) Equal amounts of protein from sham and CH cardiomyocytes 
infected with adenovirus encoding C460W/E583M CNGA2 or from non-infected (NI) sham 
cells were separated by SDS/PAGE and channel expression was subsequently detected by 
Western blotting. Expression of Calsequestrin (Calseq) was determined as a loading control. 
The intensity of the CNGA2 immunoblot signal for all samples is quantified in (B). 
Expression of C460W/E583M CNGA2 is normalized to the expression level of Calseq in 
each sample. 
